NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Clinical trial NCT05262556 · COMPLETED

Trial details

NCT number: NCT05262556
Sponsor: Amr Mohamed MD
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Gastroenteropancreatic Neuroendocrine Tumor Gastroenteropancreatic Neuroendocrine Neoplasm Neuroendocrine Carcinoma Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

Start date: 2022-12-15
Primary completion: 2025-10-27
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.